More and more drugmakers are outsourcing their drug trials to contract research organizations, says Pharmalot's Ed Silverman. So it should come as no surprise that CROs are the latest sector to see some large acquisitions and interest from investors.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have an account?
Login Now.